Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06045806 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06045806 · ClinicalTrials.gov record · last posted 2026-03-05

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Study acronym: KarMMa-9
StatusActive, Not Recruiting
PhasePhase 3
SponsorCelgene
Started2023-10-16
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).

Amendment record 30 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 30 times since 2023-09-13; most recent amendment 2026-03-04. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-09-25
Status change Recruiting→Active, Not Recruitingv28
2023-10-19
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06045806
Lead Sponsor Celgene
Collaborators: Bristol-Myers Squibb, 2seventy bio
Conditions Multiple Myeloma
Enrollment 79 participants
Start Date 2023-10-16
Primary Completion 2025-08-11 (estimated)
Study Completion 2029-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-05